RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL — Stella

Home/Double-expressor Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to Double-expressor Lymphoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Key details

Phase

Safety & dosing

Sponsor

Zhejiang Cancer Hospital

Enrollment target

~44 participants

Started

November 2024

Primary completion

December 2029

Age range

65 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.